Drugs / CUDAROLIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03758001 | Feb 2019 → Feb 2023 | neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-12-05 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101 innoventbio.com ↗
IBI101 is the third molecule from Innovent approved for clinical trials by FDA. |
| 2018-07-26 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Receives IND Approval to Initiate Clinical Trials in China with its anti-OX40 Agonistic Antibody IBI101 and its anti-RANKL Antibody IBI307 innoventbio.com ↗
Innovent’s IBI101, is the first OX40-targeted molecule to receive IND approval in China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-05 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101 innoventbio.com ↗ |
| 2018-07-26 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Receives IND Approval to Initiate Clinical Trials in China with its anti-OX40 Agonistic Antibody IBI101 and its anti-RANKL Antibody IBI307 innoventbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUDAROLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594552 ↗ |
| Known as | IBI101 | “IBI101 is a recombinant fully humanized IgG1 anti-tumor necrosis factor receptor superfamily member 4 (OX40) monoclonal antibody.” NCT03758001 ↗ |
| Modality | Monoclonal antibody | “IBI101 is a recombinant fully humanized IgG1 anti-tumor necrosis factor receptor superfamily member 4 (OX40) monoclonal antibody.” NCT03758001 ↗ |
| Route | Intravenous | “IBI101 and Sintilimab will be administered intravenously on Day 1 of every 21-day cycle.” NCT03758001 ↗ |